Business Context and Reporting Period
This Form 10-QSB covers the quarterly period ended June 30, 2001, for Atlantic Technology Ventures, Inc. (Note: The request metadata listed "TG THERAPEUTICS, INC.", but the filing text identifies the issuer as Atlantic Technology Ventures, Inc., a development-stage company). The company focuses on biotechnology and superconducting electronics, operating through subsidiaries including Optex Ophthalmologics, Inc. and Gemini Technologies, Inc.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2001 | Six Months Ended June 30, 2000 |
|---|---|---|
| Total Revenues | $2,711,922 | $2,360,124 |
| Net Loss | $(434,231) | $(4,465,600) |
| Net Loss Applicable to Common Shares | $(1,265,502) | $(5,124,919) |
| Net Loss Per Common Share (Basic/Diluted) | $(0.19) | $(0.98) |
| Cash and Cash Equivalents (End of Period) | $1,030,363 | $1,605,801 |
| Working Capital | $333,300 | $(201,274) |
| Accumulated Deficit (Inception to Date) | $(25,427,692) | N/A |
Liquidity: The company reported a cash burn rate of approximately $200,000 per month. Management anticipates current resources will fund operations for "at least the next several months."
Material Changes vs. Prior Period
- Revenue Composition: Revenue increased slightly year-over-year, driven by a $1.07 million project completion bonus from Bausch & Lomb recognized in Q1 2001. However, development revenue ceased in Q2 2001 following the termination of the Bausch & Lomb agreement.
- Asset Sales:
- Optex Assets: Sold substantially all assets to Bausch & Lomb for $3.0 million, recording a net gain of $2,569,451 (net of $240,000 severance payments).
- Gemini Assets: Sold assets to IFN, Inc. (Cleveland Clinic affiliate) for contingent royalties, recording a loss of $334,408.
- Expense Reductions: Significant reduction in "Acquired in-process research and development" expenses ($2.39 million in 2000 vs. $0 in 2001) and stock warrant compensation expenses ($1.06 million in 2000 vs. $34,666 in 2001).
- Expense Increases: General and administrative expenses rose due to a $444,000 non-cash expense for commitment shares issued to Fusion Capital and a $120,000 finder's fee.
Guidance, Outlook, and Risks
- Financing Contingency: The company entered a $6.0 million common stock purchase agreement with Fusion Capital Fund II, LLC. However, the company is currently unable to draw funds because its stock price is below the $0.68 floor price specified in the agreement.
- Delisting Risk: The company is at risk of being delisted from the Nasdaq SmallCap Market due to failure to maintain a minimum bid price of $1.00 for 30 consecutive days. A hearing was held on August 9, 2001, with a decision pending.
- Operational Outlook: Management plans to cut or delay development activities if additional capital cannot be raised. Future revenue is expected to rely on royalties from the Optex sale and potential licensing of the CT-3 compound.
- Unusual Items: The net loss for the six-month period was significantly reduced by the $2.57 million gain on the Optex asset sale. Without this one-time gain, the operating loss would have been substantial.
Investor Verification Checklist
- Stock Price Floor: Verify if the stock price has risen above $0.68 to enable funding under the Fusion Capital agreement.
- Nasdaq Status: Confirm the outcome of the Nasdaq Listing Qualifications Panel hearing regarding delisting.
- Cash Runway: Assess the current cash balance against the stated $200,000 monthly burn rate to determine immediate liquidity needs.
- Optex Royalties: Monitor Bausch & Lomb's progress on regulatory approval in Japan to trigger the $1.0 million contingent payment.
- Preferred Stock: Review the status of Series A convertible preferred stock dividends and their impact on common shareholder equity.